AXA SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 34.84 USD | +0.49% |
|
+1.60% | +6.59% |
| Jul. 11 | Cognizant Names Karima Silvent to Board of Directors | CI |
| Jul. 11 | Researchers advise lessons to be learned from serious cycling accidents on country roads | DP |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- With regards to fundamentals, the enterprise value to sales ratio is at 0.78 for the current period. Therefore, the company is undervalued.
- This company will be of major interest to investors in search of a high dividend stock.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Ratings chart - Surperformance
Sector: Life & Health Insurance
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +6.59% | 76.18B | - | ||
| +12.02% | 51.26B | B | ||
| +9.54% | 50.93B | B+ | ||
| +26.71% | 48.52B | B+ | ||
| +18.00% | 43.23B | B+ | ||
| +23.37% | 39.51B | B | ||
| +18.80% | 34.08B | B | ||
| -0.71% | 28.85B | B | ||
| +43.17% | 28.59B | A | ||
| +52.57% | 27.71B | B |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- CS Stock
- AXAH.Y Stock
- Ratings AXA SA
